Document:

EXECUTION
COPY

CONFIDENTIAL

 

STOCK ISSUANCE AGREEMENT

 

 

 

This
Agreement (“Agreement”) is made and entered into as of August 6, 2012 (the “Effective Date”),
by and among Synthetic Biologics, Inc., a Nevada corporation (the “Company”), and Intrexon Corporation, a Virginia
corporation (“Intrexon”).

 

A.Concurrently
with the execution of this Agreement, the Company is entering into an Exclusive Channel Collaboration Agreement with Intrexon (the
“Channel Agreement”), pursuant to which Intrexon is licensing the rights to certain technology to the Company;
and

 

B.In partial
consideration of Intrexon’s license to the Company under the Channel Agreement, the Company has agreed to issue to Intrexon
certain shares of the Company’s common stock, par value $0.001 per share, (the “Common Stock”) in accordance
with the terms and conditions of this Agreement.

 

 

 

AGREEMENT

 

In consideration of
the mutual covenants contained in this Agreement and for other good and valuable consideration, the receipt of which is hereby
acknowledged, the Company and Intrexon hereby agree as follows:

 

 

 

sECTION
1.    Authorization
of Issuance of Shares.

 

1.1             
Technology Access Fee. Subject to the terms and conditions of this Agreement, the Company has authorized
the issuance to Intrexon of a certain number of shares of the Company’s Common Stock at the Technology Access Fee Closing
(as hereinafter defined) as a technology access fee (the “Technology Access Fee Shares”), which number of Technology
Access Fee Shares is equal to the difference between (i) 19.99% of the number of shares of Common Stock of Company outstanding
as of the date of the Technology Access Fee Closing prior to the issuance of such shares, and (ii) the number of shares of Common
Stock of Company held by Intrexon immediately prior to the Technology Access Fee Closing.

 

1.2             
Milestones. Subject to the terms and conditions of this Agreement and the Channel Agreement, upon the
attainment of certain commercialization milestones as for each Synthetic Product (as that term is defined in the Channel Agreement)
developed under the Channel Agreement that reach such milestones, the Company has agreed to make milestone payments (each, whether
in cash or equity, a “Milestone Payment” and together “Milestone Payments”) set forth below
in Sections 1.2(a) and 1.2(b) to Intrexon, at the option of the Company, payable either in cash or in shares of Company Common
Stock at the option of the Company, on certain dates following achievement of certain Milestone Events (as defined below).

 

    	1.

    	EXECUTION COPY
CONFIDENTIAL

    
 

(a)              
Upon the filing of an Investigational New Drug application with the U.S. Food and Drug Administration for a Synthetic
Product, or alternatively the filing of the first equivalent regulatory filing with a foreign regulatory agency (both as applicable,
the “IND Milestone Event”), Company will pay to Intrexon either (i) two million dollars ($2M) in cash, or (ii)
that number of shares of Common Stock (the “IND Milestone Shares”) having a fair market value equaling two million
dollars ($2M) where such fair market value for this Section 1.2(a) is determined using published market data of the share price
for Common Stock at the close of market on the business day immediately preceding the date of public announcement of attainment
of the IND Milestone Event.

 

(b)              
Upon the first to occur of either first commercial sale of a Synthetic Product in a country or the granting of
the regulatory approval of that Synthetic Product (both as applicable, the “Approval Milestone Event”), Company
will pay to Intrexon either (i) three million dollars ($3M) in cash, or (ii) that number of shares of Common Stock (the “Approval
Milestone Shares”) having a fair market value equaling three million dollars ($3M) where such fair market value for this
Section 1.2(b) is determined using published market data of the share price for Common Stock at the close of market on the business
day immediately preceding the date of public announcement of attainment of the Approval Milestone Event.

 

The number of shares
of Common Stock to be issued under each of subsections (a) and (b) of this Section 1.2 shall be rounded down to the nearest whole
share. The event giving rise to an issuance of shares under subsections (a) and (b) of this Section 1.2 shall be a “Milestone
Event” and together, the “Milestone Events.” A Milestone Payment shall be due within thirty days following
the date of the occurrence of a Milestone Event.

 

1.3             
Field Expansion Fee. As set forth in Section 2.1(e) of the Channel Agreement, Company has agreed that
it will pay an optional and varying fee whereby Synthetic remits a payment, in cash or equity at Synthetic’s sole discretion,
to Intrexon for each additional indication elected under Section 2.1(e) of the Channel Agreement (the “Field Expansion
Fee”). For clarity, if the Field, following the Field election by Synthetic required per Section 2.1(c) of the Channel
Agreement, contains three (3) total or less targets, then neither this Section 1.3 nor Section 2.1(e) of the Channel Agreement
will trigger any obligation for Synthetic to pay a Field Expansion Fee irrespective of whether any of such three (3) total or less
targets have been previously swapped in by Synthetic for other targets in accord with Section 2.1(b) of the Channel Agreement.
The Field Expansion Fee must be paid completely in either Common Stock or cash, and will comprise either (i) two million dollars
($2M) in cash for each such additional target elected under Section 2.1(e) of the Channel Agreement, or (ii) that number of shares
of Common Stock (the “Field Expansion Fee Shares”) having a fair market value equaling two million dollars ($2M)
for each such target that Company will so elect where such fair market value for this Section 1.3 is determined using published
market data establishing the volume-weighted average price for a share of Common Stock over the thirty (30) day period immediately
preceding the date of the Field Expansion Fee Closing (as defined below).

 

    	2.

    	EXECUTION COPY
CONFIDENTIAL

    
 

1.4             
Capital Adjustments. If after the date hereof (i) the outstanding shares of the Company’s Common
Stock shall be subdivided or split into a greater number of shares or a dividend in Common Stock shall be paid in respect of such
Common Stock or (ii) the outstanding shares of Common Stock are combined, then all share quantities in this Agreement not yet issued
shall be appropriately adjusted to reflect such stock split, stock dividend or conjunction. If after the date hereof (i) the Company
shall pay a dividend in securities of the Company (other than in Common Stock) or of other property (including cash) on the Common
Stock, or (ii) there shall occur any merger, consolidation, capital reorganization or reclassification in which the Common Stock
is converted or exchanged for securities, cash or other property, the class or series of stock constituting the Common Stock for
purposes of this Agreement, shall be appropriately adjusted to reflect such other dividend, merger, consolidation, capital reorganization
or reclassification. After any event referenced in clauses (i) through (ii) of the immediately preceding sentence is consummated,
if applicable, all references herein to the Company’s Common Stock shall be deemed to refer to the capital stock or property
(including cash) into or for which the Common Stock was converted or exchanged, with the necessary changes in detail. Nothing contained
in this Section 1.2 or elsewhere in this Agreement will prevent or prohibit the dilution of Intrexon’s ownership interest
in the Company or grant to Intrexon any preemptive rights.

 

1.5             
Company Sale. In the event that the Company consummates a Company Sale (as defined below) prior to any
one of the Subsequent Closings (as defined below), and the Channel Agreement is transferred or assigned to the buyer or assigned
to the buyer in connection with such Company Sale, the Company and Intrexon agree that payments under Sections 1.2 and 1.3 of this
Agreement shall be payable only in cash following the Company Sale.

 

 

 

sECTION
2.    Closing
and Delivery 

 

2.1             
Sale and Purchase Price of Shares. Subject to the terms and conditions of this Agreement and in
reliance upon the representations, warranties and agreements contained herein, the Company will issue and sell to Intrexon, and
Intrexon will purchase from the Company, at each of the Technology Access Fee Closing, the Milestone Closings (as hereinafter defined)
if the Company has not elected to make the Milestone Payment in cash, and the Field Expansion Fee Closing (as hereinafter defined)
if the Company has not elected to make the Field Expansion Fee payment in cash, the applicable number of shares as set forth above
in Sections 1.1 through 1.3. The Parties agree that the consideration received by the Company hereunder shall be the execution
and delivery by Intrexon of the Channel Agreement which consideration is at least equal to the par value of the shares issued or
issuable under this Agreement.

 

2.2             
Closings. The closings of the purchase and sale of the shares to be issued pursuant to this Agreement
shall be held at the offices of Gracin & Marlow, LLP, Chrysler Building, 405 Lexington Avenue, 26th Floor, New York, New York
10174 or at such other place as the Company and Intrexon may agree, as follows:

 

(a)              
the closing of the purchase and sale of the Technology Access Fee Shares will occur, subject to the conditions
set forth in Section 7.1 hereof and applicable to the Technology Access Fee Closing, subject to the timeframes set forth in Section
5.1 of the Channel Agreement, (i) on the fourth business day following approval of the Channel Agreement by NYSE Amex (the “NYSE
Amex Approval”), or (ii) on such other date as Intrexon and the Company may agree upon (in either case, the “Technology
Access Fee Closing”);

 

    	3.

    	EXECUTION COPY
CONFIDENTIAL

    
 

(b)              
the closing of the purchase and sale of each occurrence of Milestone Shares or the payment of each Milestone
Cash Payment will occur, subject to the conditions set forth in Section 7.2 hereof and applicable to the Milestone Closing, (A)
if NYSE Amex approval (or approval of any other exchange upon which the Common Stock may be listed) is required, on the tenth (10th)
business day after such approval is received, but in no event later than one hundred twenty (120) days after the respective Milestone
Event, or (B) if NYSE Amex approval (or approval of any other exchange upon which the Common Stock may be listed) is not required,
on the earlier of (i) the thirtieth (30th) day following the occurrence of the respective Milestone Event, and (ii)
such other date as Intrexon and the Company may agree (the “Milestone Closing”); and

 

(c)               
the closing of the purchase and sale of the Field Expansion Fee Shares or the payment of the cash Field Expansion
Fee Payment will occur, subject to the conditions set forth in Section 7.2 hereof and applicable to the Field Expansion Fee Closing,
at a date and time set by Company and reasonably acceptable to Intrexon, but in no event shall that date be later than the one
year anniversary of the Channel Agreement’s effective date (the “Field Expansion Fee Closing”).

 

The Technology Access Fee Closing, each
of the Milestones Closing, and the Field Expansion Fee Closing may be collectively herein referred to as the “Closings”
and individually as a “Closing”. Further, each of the Milestones Closing and the Field Expansion Fee Closing
may be collectively herein referred to as the “Subsequent Closings” and individually as a “Subsequent
Closing”.

 

2.3             
Delivery of the Shares. Promptly following a Closing at which shares are issued to Intrexon, the Company
shall deliver to Intrexon a certificate representing the number of shares purchased at such Closing, registered in the name of
Intrexon.

 

 

 

sECTION
3.    Representations
and Warranties of the Company.

 

Subject to and except
as set forth in the SEC Documents or on the Schedule of Exceptions which is arranged in sections corresponding to the sub-section
numbered provisions contained below in this Section, the Company hereby represents and warrants to, and covenants with, Intrexon
as of the date hereof as follows:

 

    	4.

    	EXECUTION COPY
CONFIDENTIAL

    
 

 

3.1             
Organization, Good Standing and Power.

 

(a)              
The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State
of Nevada and has the requisite corporate power to own, lease and operate its properties and assets and to conduct its business
as it is now being conducted and as described in the reports filed by the Company with the Securities and Exchange Commission (the
“Commission”) pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), since the end of its most recently completed fiscal year through the date hereof, including,
without limitation, its most recent report on Form 10-Q. The Company does not have any subsidiaries other than those identified
in its most recent report on Form 10-Q. The Company is qualified to do business as a foreign corporation and is in good standing
in every jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except for any jurisdiction(s) (alone or in the aggregate) in which the failure to be so qualified will not have a Material Adverse
Effect. For the purposes of this Agreement, “Material Adverse Effect” means any effect on the business, operations,
properties or financial condition of the Company that is material and adverse to the Company, taken as a whole, and any condition,
circumstance or situation that would prohibit the Company from entering into and performing any of its obligations hereunder.

 

3.2             
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into
and perform this Agreement and to issue and sell the shares in accordance with the terms hereof. The execution, delivery and performance
of this Agreement by the Company and the consummation by it of the transactions contemplated hereby have been duly and validly
authorized by all necessary corporate action, and no further consent or authorization of the Company, its board of directors or
stockholders is required, except pursuant to Section 7. When executed and delivered by the Company, this Agreement shall constitute
a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as such enforceability
may be limited by applicable bankruptcy, reorganization, moratorium, liquidation, conservatorship, receivership or similar laws
relating to, or affecting generally the enforcement of, creditor’s rights and remedies or by other equitable principles of
general application. The Company’s board of directors, at a meeting duly called and held, adopted resolutions approving the
transactions contemplated hereby, including the issuance of the Technology Access Fee Shares, the Field Expansion Fee Shares, and
the Milestone Shares issuable upon occurrence of the various Milestone Events in a manner consistent with and that meets the requirements
of Nevada Corporate Code contained in Chapter 78 of the Nevada Revised Statutes.

 

3.3             
Issuance of Shares. The shares to be issued and sold hereunder have been duly authorized by all necessary
corporate action and, when paid for and issued in accordance with the terms hereof, will be validly issued, fully paid and nonassessable.
In addition, such shares will be free and clear of all liens, claims, charges, security interests or agreements, pledges, assignments,
covenants, restrictions or other encumbrances created by, or imposed by, the Company (collectively, “Encumbrances”)
and rights of refusal of any kind imposed by the Company (other than restrictions on transfer under applicable securities laws)
and the holder of such shares shall be entitled to all rights accorded to a holder of Common Stock. As of the date hereof, 32,701,984
shares of the Company’s Common Stock are issued and outstanding.

 

    	5.

    	EXECUTION COPY
CONFIDENTIAL

    
 

 

3.4             
No Conflicts; Governmental Approvals. The execution, delivery and performance of the Agreement by the
Company and the consummation by the Company of the transactions contemplated hereby do not and will not (i) violate any provision
of the Company’s Articles of Incorporation or Bylaws, each as amended to date, (ii) conflict with, or constitute a default
(or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination,
amendment, acceleration or cancellation of, any agreement, mortgage, deed of trust, indenture, note, bond, license, lease agreement,
instrument or obligation to which the Company is a party or by which the Company’s properties or assets are bound, or (iii)
result in a violation of any federal, state, local or foreign statute, rule, regulation, order, judgment or decree (including federal
and state securities laws and regulations) applicable to the Company or by which any property or asset of the Company is bound
or affected, except for such conflicts, defaults, terminations, amendments, acceleration, cancellations and violations as would
not, individually or in the aggregate, have a Material Adverse Effect. The Company is not required under federal, state, foreign
or local law, rule or regulation to obtain any consent, authorization or order of, or make any filing or registration with, any
court or governmental agency in order for it to execute, deliver or perform any of its obligations under this Agreement or issue
and sell the shares in accordance with the terms hereof (other than any filings, consents and approvals which may be required to
be made by the Company under applicable state and federal securities laws, rules or regulations prior to or subsequent to the Closing).
The sale and issuance of the shares hereunder will be required to be approved in advance by NYSE Amex.

 

3.5             
SEC Documents, Financial Statements. The Common Stock of the Company is registered pursuant to Section
12(b) of the Exchange Act. During the two year period preceding the execution of this Agreement other than with respect to its
Annual Report on Form 10-K for the year ended December 31, 2011, the Company has timely filed all reports, schedules, forms, statements
and other documents required to be filed by it with the Commission pursuant to the reporting requirements of the Exchange Act (the
“SEC Documents”). At the times of their respective filing other than with respect to its initial Annual Report
on Form 10-K for the year ended December 31, 2011, all such reports, schedules, forms, statements and other documents complied
in all material respects with the requirements of the Exchange Act and the rules and regulations of the Commission promulgated
thereunder. At the times of their respective filings, such reports, schedules, forms, statements and other documents did not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein, in light of the circumstances under which they were made, not misleading. As of their respective dates,
other than with respect to its initial Annual Report on Form 10-K for the year ended December 31, 2011 the financial statements
of the Company included in the SEC Documents complied in all material respects with applicable accounting requirements and the
published rules and regulations of the Commission or other applicable rules and regulations with respect thereto. Such financial
statements have been prepared in accordance with generally accepted accounting principles applied on a consistent basis during
the periods involved (except (i) as may be otherwise indicated in such financial statements or the notes thereto or (ii) in the
case of unaudited interim statements, to the extent they may not include footnotes or may be condensed or summary statements),
and fairly present in all material respects the consolidated financial position of the Company as of the dates thereof and the
results of operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end
audit adjustments).

 

    	6.

    	EXECUTION COPY
CONFIDENTIAL

    
 

3.6             
Accountants. Berman & Company, P.A. whose report on the financial statements of the Company is filed
with the SEC in the Company’s Annual Report on Form 10-K/A for the year ended December 31, 2011 filed with the SEC on May
11, 2012, were, at the time such report was issued, independent registered public accountants as required by the Securities Act
of 1933 and the rules and regulations promulgated thereunder (together, the “Securities Act”). Except as described
in the SEC Documents and as preapproved in accordance with the requirements set forth in Section 10A of the Exchange Act, to the
Company’s knowledge, Berman & Company, P.A. has not engaged in any non-audit services prohibited by subsection (g) of
Section 10A of the Exchange Act on behalf of the Company.

 

3.7             
Internal Controls. The Company has established and maintains a system of internal accounting controls
sufficient to provide reasonable assurances that: (i) transactions are executed in accordance with management’s general or
specific authorization; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with generally accepted accounting principles in the United States and to maintain accountability for assets; (iii) access to assets
is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

 

3.8             
Corporate Governance. The Company’s board of directors meets the independence requirements of, and
has established an audit committee that meets the independence requirements of, the rules and regulations of the Commission and
the NYSE Amex (formerly the American Stock Exchange). The Audit Committee has reviewed the adequacy of its charter within the past
12 months.

 

3.9             
Disclosure Controls. The Company has established and maintains disclosure controls and procedures (as
such term is defined in Rules 13a-15 and 15d-15 under the Exchange Act). Since the date of the most recent evaluation of such disclosure
controls and procedures, there have been no significant changes in internal controls or in other factors that could significantly
affect internal controls, including any corrective actions with regard to significant deficiencies and material weaknesses. The
Company is in compliance in all material respects with all provisions currently in effect and applicable to the Company of the
Sarbanes-Oxley Act of 2002, and all rules and regulations promulgated thereunder or implementing the provisions thereof.

 

3.10         
No Material Adverse Change. Except as disclosed in the SEC Documents, since March 31, 2012, the Company
has not (i) experienced or suffered any Material Adverse Effect, (ii) incurred any material liabilities, obligations, claims or
losses (whether liquidated or unliquidated, secured or unsecured, absolute, accrued, contingent or otherwise) other than those
incurred in the ordinary course of the Company’s business or (iii) declared, made or paid any dividend or distribution of
any kind on its capital stock.

 

3.11         
No Undisclosed Events or Circumstances. Except as disclosed in the SEC Documents, since March 31, 2012,
except for the consummation of the transactions contemplated herein, to the Company’s knowledge, no event or circumstance
has occurred or exists with respect to the Company or its businesses, properties, prospects, operations or financial condition,
which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been
so publicly announced or disclosed.

 

    	7.

    	EXECUTION COPY
CONFIDENTIAL

    
 

3.12         
Litigation. No action, suit, proceeding or investigation is currently pending or, to the knowledge of
the Company, has been threatened in writing against the Company that: (i) concerns or questions the validity of this Agreement;
(ii) concerns or questions the right of the Company to enter into this Agreement; or (iii) is reasonably likely to have a Material
Adverse Effect. The Company is neither a party to nor subject to the provisions of any material order, writ, injunction, judgment
or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or investigation by the Company
currently pending or that the Company intends to initiate that would have a Material Adverse Effect.

 

3.13         
Compliance. Except for defaults or violations which are not reasonably likely to have a Material Adverse
Effect, the Company is not (i) in default under or in violation of (and no event has occurred that has not been waived that, with
notice or lapse of time or both, would result in a default by the Company under), nor has the Company received notice of a claim
that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument
to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived),
(ii) is in violation of any order of any court, arbitrator or governmental body, or (iii) is or has been in violation of any statute,
rule or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws, applicable
to its business, except in each case for such defaults or violations as would not have a Material Adverse Effect.

 

3.14         
Intellectual Property

 

(a)              
To the best of its knowledge, the Company has entered into agreements with each of its current and former officers,
employees and consultants involved in research and development work, including development of the Company’s products and
technology providing the Company, to the extent permitted by law, with title and ownership to patents, patent applications, trade
secrets and inventions conceived, developed, reduced to practice by such person, solely or jointly with other of such persons,
during the period of employment by the Company except where the failure to have entered into such an agreement would not have a
Material Adverse Effect. The Company is not aware that any of its employees or consultants is in material violation thereof.

 

(b)              
To the Company’s knowledge, the Company owns or possesses adequate rights to use all, if any, trademarks,
service marks, trade names, domain names, copyrights, patents, patent applications, inventions, know how (including trade secrets
and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), and other intellectual
property rights (“Intellectual Property”) as are necessary for the conduct of its business as described in the
SEC Documents. Except as described in the SEC Documents, (i) to the knowledge of the Company, there is no infringement, misappropriation
or violation by third parties of any such Intellectual Property; (ii) there is no pending or, to the knowledge of the Company,
threatened action, suit, proceeding or claim by others against the Company challenging the Company’s rights in or to any
such Intellectual Property; (iii) the Intellectual Property owned by the Company and, to the knowledge of the Company, the
Intellectual Property licensed to the 

 

    	8.

    	EXECUTION COPY
CONFIDENTIAL

    

Company has not been adjudged invalid or unenforceable by a court of competent jurisdiction or applicable government agency, in
whole or in part, and there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by
others challenging the validity or scope of any such Intellectual Property; (iv) there is no pending or, to the knowledge of the
Company, threatened action, suit, proceeding or claim by others against the Company that the Company infringes, misappropriates
or otherwise violates any Intellectual Property or other proprietary rights of others, and the Company has not received any written
notice of such claim; and (v) to the Company’s knowledge, no employee of the Company is the subject of any claim or
proceeding involving a violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement,
non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former
employer where the basis of such violation relates to such employee’s employment with the Company or actions undertaken
by the employee while employed with the Company, in each of (i) through (v), for any instances which would not, individually or
in the aggregate, result in a Material Adverse Effect.

 

3.15         
FDA Compliance.

 

(a)              
Except as described in the SEC Documents, the Company: (i) is in material compliance with all statutes, rules
or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing,
labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product that is under development, manufactured
or distributed by the Company (“Applicable Laws”); (ii) has not received any FDA Form 483, notice of adverse
finding, warning letter, untitled letter or other correspondence or notice from the U.S. Food and Drug Administration (the “FDA”)
or any other federal, state, local or foreign governmental or regulatory authority alleging or asserting material noncompliance
with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments
thereto required by any such Applicable Laws (“Authorizations”), which would not, individually or in the aggregate,
result in a Material Adverse Effect; (iii) possesses all material Authorizations necessary for the operation of its business as
described in the SEC Documents and such Authorizations are valid and in full force and effect and the Company is not in material
violation of any term of any such Authorizations; and (iv) since December 31, 2011: (A) has not received notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any other federal, state, local
or foreign governmental or regulatory authority or third party alleging that any product operation or activity is in material violation
of any Applicable Laws or Authorizations and the Company has no knowledge that the FDA or any other federal, state, local or foreign
governmental or regulatory authority or third party is considering any such claim, litigation, arbitration, action, suit, investigation
or proceeding; (B) has not received notice that the FDA or any other federal, state, local or foreign governmental or regulatory
authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has
no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority is considering such
action; (C) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records,
claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports,
documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and
correct on the date filed (or were corrected or supplemented by a subsequent submission); and (D) has not, either voluntarily or
involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal or
replacement, safety alert, post sale warning, “dear doctor” letter, or other notice or action relating to the alleged
lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company’s knowledge, no
third party has initiated, conducted or intends to initiate any such notice or action.

 

    	9.

    	EXECUTION COPY
CONFIDENTIAL

    
 

(b)              
 Since January 1, 2009, and except to the extent disclosed in the SEC Documents, the Company has not received
any notices or correspondence from the FDA or any other federal, state, local or foreign governmental or regulatory authority requiring
the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on
behalf of the Company.

 

3.16         
General Healthcare Regulatory Compliance.

 

(a)              
As used in this subsection:

 

(i)                
“Governmental Entity” means any national, federal, state, county, municipal, local or foreign
government, or any political subdivision, court, body, agency or regulatory authority thereof, and any Person exercising executive,
legislative, judicial, regulatory, taxing or administrative functions of or pertaining to any of the foregoing.

 

(ii)              
“Law” means any federal, state, local, national or foreign law, statute, code, ordinance,
rule, regulation, order, judgment, writ, stipulation, award, injunction, decree or arbitration award or finding.

 

(b)              
The Company has not committed any act, made any statement or failed to make any statement that would reasonably
be expected to provide a basis for the FDA or any other Governmental Entity to invoke its policy with respect to “Fraud,
Untrue Statements of Material Facts, Bribery, and Illegal Gratuities”, or similar policies, set forth in any applicable Laws.
Neither the Company, nor, to the knowledge of the Company, any of its officers, key employees or agents has been convicted of any
crime or engaged in any conduct that has resulted, or would reasonably be expected to result, in debarment under applicable Law,
including, without limitation, 21 U.S.C. Section 335a. No claims, actions, proceedings or investigations that would reasonably
be expected to result in such a material debarment or exclusion are pending, or to the knowledge of the Company, threatened, against
the Company or any of its respective officers, employees or agents.

 

(c)               
Each of the Company and, to its knowledge, its directors, officers, employees, and agents (while acting in such
capacity) is, and at all times has been, in material compliance with all health care Laws applicable to the Company or by which
any of its properties, businesses, products or other assets is bound or affected, including, without limitation, the federal Anti-kickback
Statute (42 U.S.C. § 1320a-7b(b)), the Anti-Inducement Law (42 U.S.C. § 1320a-7a(a)(5)), the civil False Claims
Act (31 U.S.C. §§ 3729 et seq.), the administrative False Claims Law (42 U.S.C. § 1320a-7b(a)), the Health Insurance
Portability and Accountability Act of 1996 (42 U.S.C. § 1320d et seq.), the exclusion laws (42 U.S.C. § 1320a-7), the
Food Drug and Cosmetic Act (21 U.S.C. §§ 301 et seq.) (collectively, “Health Care Laws”). The Company
has not received any notification, correspondence or any other written or oral communication from any Governmental Entity, including,
without limitation, the FDA, the Centers for Medicare and Medicaid Services, and the Department of Health and Human Services Office
of Inspector General, of potential or actual material non-compliance by, or liability of, the Company under any Health Care Laws.

 

    	10.

    	EXECUTION COPY
CONFIDENTIAL

    
 

(d)              
The Company is not a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement
orders, or similar agreements with or imposed by any Governmental Entity.

 

3.17         
Application of Takeover Protections. The issuance of the shares hereunder and Intrexon’s ownership
thereof is not prohibited by the business combination statutes of the state of Nevada. The Company has not adopted any stockholder
rights plan, “poison pill” or similar arrangement that would trigger any right, obligation or event as a result of
the issuance of such shares and Intrexon’s ownership of such shares and there are no similar anti-takeover provisions under
the Company's charter documents.

 

3.18         
Listing and Maintenance Requirements. The Company is in compliance with the requirements of the NYSE Amex
(formerly the American Stock Exchange) for continued listing of the Company common stock thereon and has not received any notification
that, and has no knowledge that NYSE Amex is contemplating terminating such listing. The issuance and sale of the shares hereunder
does not contravene the rules and regulations of the NYSE Amex in any material respect, provided such sale and issuance is approved
in advance by NYSE Amex.

 

3.19         
Private Placement. Neither the Company nor its Affiliates, nor any Person acting on its or their behalf,
(i) has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D under the Securities
Act) in connection with the offer or sale of the shares hereunder, (ii) has, directly or indirectly, made any offers or sales of
any security or solicited any offers to buy any security, under any circumstances that would require registration of the sale and
issuance by the Company of the Technology Access Fee Shares, the Milestone Shares, and Field Expansion Shares under the Securities
Act or (iii) has issued any shares of Common Stock or shares of any series of preferred stock or other securities or instruments
convertible into, exchangeable for or otherwise entitling the holder thereof to acquire shares of Common Stock which would be integrated
with the sale of the Common Stock to Intrexon for purposes of the Securities Act or of any applicable stockholder approval provisions,
including, without limitation, under the rules and regulations of any exchange or automated quotation system on which any of the
securities of the Company are listed or designated, nor will the Company or any of its subsidiaries or affiliates take any action
or steps that would require registration of any of the Common Stock under the Securities Act or cause the offering of the Common
Stock to be integrated with other offerings. Assuming the accuracy of the representations and warranties of Intrexon, the offer
and sale of the Common Stock by the Company to Intrexon pursuant to this Agreement will be exempt from the registration requirements
of the Securities Act.

 

3.20         
No Manipulation of Stock. The Company has not taken and will not, in violation of applicable law,
take, any action outside the ordinary course of business designed to or that might reasonably be expected to cause or result in
unlawful manipulation of the price of the Common Stock.

 

    	11.

    	EXECUTION COPY
CONFIDENTIAL

    
 

3.21         
Brokers. Neither the Company nor any of the officers, directors or employees of the Company has employed
any broker or finder in connection with the transaction contemplated by this Agreement. The Company shall indemnify Intrexon from
and against any broker’s, finder’s or agent’s fees for which the Company is responsible.

 

 

sECTION
4.    Representations,
Warranties and Covenants of Intrexon.

 

Intrexon hereby represents
and warrants to, and covenants with, the Company as of the date hereof as follows:

 

4.1             
Purchaser Sophistication. Intrexon (a) is knowledgeable, sophisticated and experienced in making, and
is qualified to make decisions with respect to, investments in shares presenting an investment decision like that involved in the
purchase of the shares, including investments in securities issued by the Company and investments in comparable companies, and
has requested, received, reviewed and considered all information it deemed relevant in making an informed decision to purchase
the shares; (b) Intrexon, in connection with its decision to purchase the shares, relied only upon the SEC Documents, other publicly
available information, and the representations and warranties of the Company contained herein; (c) Intrexon is an "accredited
investor" pursuant to Rule 501 of Regulation D under the Securities Act; (d) Intrexon is acquiring the shares for its own
account for investment only and with no present intention of distributing any of such shares or any arrangement or understanding
with any other persons regarding the distribution of such shares; (e) Intrexon has not been organized, reorganized or recapitalized
specifically for the purpose of investing in the shares; (f) Intrexon will not, directly or indirectly, offer, sell, pledge,
transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire to take a pledge of) any of the shares
except in compliance with the Securities Act and applicable state securities laws; (g) Intrexon understands that the shares are
being offered and sold to it in reliance upon specific exemptions from the registration requirements of the Securities Act and
state securities laws, and that the Company is relying upon the truth and accuracy of, and Intrexon’s compliance with, the
representations, warranties, agreements, acknowledgments and understandings of Intrexon set forth herein in order to determine
the availability of such exemptions and the eligibility of Intrexon to acquire the shares; (h) Intrexon understands that its investment
in the shares involves a significant degree of risk, including a risk of total loss of Intrexon’s investment (provided that
such acknowledgment in no way diminishes the representations, warranties and covenants made by the Company hereunder); and (i)
Intrexon understands that no United States federal or state agency or any other government or governmental agency has passed upon
or made any recommendation or endorsement of the shares.

 

    	12.

    	EXECUTION COPY
CONFIDENTIAL

    
 

4.2             
Authorization and Power. Intrexon has the requisite power and authority to enter into and perform this
Agreement and to purchase the shares being sold to it hereunder. The execution, delivery and performance of this Agreement by Intrexon
and the consummation by it of the transactions contemplated hereby have been duly authorized by all necessary corporate action,
and no further consent or authorization of Intrexon or its board of directors or stockholders is required. When executed and delivered
by Intrexon, this Agreement shall constitute a valid and binding obligation of Intrexon enforceable against Intrexon in accordance
with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation, conservatorship, receivership or similar laws relating to, or affecting generally the enforcement of, creditor’s
rights and remedies or by other equitable principles of general application.

 

4.3             
No Conflict. The execution, delivery and performance of this Agreement by Intrexon and the consummation
by Intrexon of the transactions contemplated hereby do not and will not (i) violate any provision of Intrexon’s charter or
organizational documents, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would
become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement,
mortgage, deed of trust, indenture, note, bond, license, lease agreement, instrument or obligation to which Intrexon is a party
or by which Intrexon’s properties or assets are bound, or (iii) result in a violation of any federal, state, local or foreign
statute, rule, regulation, order, judgment or decree (including federal and state securities laws and regulations) applicable to
Intrexon or by which any property or asset of Intrexon are bound or affected, except, in all cases, other than violations (with
respect to federal and state securities laws) above, for such conflicts, defaults, terminations, amendments, acceleration, cancellations
and violations as would not, individually or in the aggregate, materially and adversely affect Intrexon’s ability to perform
its obligations under the Agreement.

 

4.4             
Restricted Shares. Intrexon acknowledges that the Technology Access Fee Shares, the Milestone Shares,
and the Field Expansion Shares are restricted securities and must be held indefinitely unless subsequently registered under the
Securities Act or the Company receives an opinion of counsel reasonably satisfactory to the Company that such registration is not
required. Intrexon is aware of the provisions of Rule 144 promulgated under the Securities Act which permit limited resale of stock
purchased in a private placement subject to the satisfaction of certain conditions, including, among other things, the existence
of a public market for the stock, the availability of certain current public information about the Company, the resale occurring
not less than one year after a party has purchased and paid for the stock to be sold, the sale being through a “broker’s
transaction” or a transaction directly with a “market maker” and the number of shares of the stock being sold
during any three-month period not exceeding specified limitations. Intrexon further acknowledges and understands that the Company
may not be satisfying the current public information requirement of Rule 144 at the time Intrexon wishes to sell the shares and,
if so, Intrexon would be precluded from selling the shares under Rule 144 even if the one year minimum holding period has been
satisfied.

 

4.5             
Ownership of Common Stock. As of the date hereof, excluding the shares, Intrexon and its Affiliates beneficially
own no shares of Common Stock of the Company.

 

4.6             
Stock Legends. Intrexon acknowledges that certificates evidencing the shares shall bear a restrictive
legend in substantially the following form (and including related stock transfer instructions and record notations):

 

    	13.

    	EXECUTION COPY
CONFIDENTIAL

    
 

THESE SECURITIES
HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY.

 

 

sECTION
5.    Survival
of Representations, Warranties and Agreements.

 

Notwithstanding any
investigation made by any party to this Agreement, all representations and warranties made by the Company and Intrexon herein shall
survive the execution of this Agreement and the issuance and sale to Intrexon of the shares and shall terminate two years after
the later of Technology Access Fee Closing or the Field Expansion Shares Closing, provided, however, the representations and warranties
in Sections 3.1, 3.2, 3.3, 4.1, 4.3, 4.4, 4.5 and 4.6 shall survive for so long as Intrexon continues to hold any of the shares
issued hereunder.

 

 

sECTION
6.    Covenants.

 

6.1             
Notifications.

 

(a)              
During the period prior to the Technology Access Fee Closing, the Company will promptly advise Intrexon in writing
of (i) any Material Adverse Effect, or (ii) any notice or other communication from any third person or entity alleging that the
consent of the third person is required in connection with the transactions contemplated by this Agreement.

 

(b)              
During the period prior to the Field Expansion Shares Closings, each party shall promptly notify the other of
any action, suit or proceeding that is instituted or specifically threatened in writing against such party to restrain, prohibit
or otherwise challenge the legality of any transaction contemplated by this Agreement.

 

(c)               
During the period prior to each of the Milestone Closings, each party shall promptly notify the other of any
action, suit or proceeding that is instituted or specifically threatened in writing against such party to restrain, prohibit or
otherwise challenge the legality of any transaction contemplated by this Agreement.

 

(d)              
Information received by Intrexon pursuant to this Section 6.1 shall be considered “Confidential Information”
as such term is defined in the Channel Agreement and Intrexon agrees to treat such information in accordance with the provisions
of Article 7 of the Channel Agreement.

 

    	14.

    	EXECUTION COPY
CONFIDENTIAL

    
 

6.2             
Compliance. The Company shall use commercially reasonable best efforts to (i) cause the Common Stock to
continue to be registered under the Exchange Act, file all periodic reports thereunder and continue the listing or trading of the
Common Stock on the NYSE Amex or any successor market (or other exchange upon which the Common Stock may be listed) in good standing
and to comply in all material respects with all applicable rules and regulations of the Commission and all reporting requirements
under the rules and regulations of the Exchange Act and (ii) to satisfy the current public information requirement of Rule 144,
in each case for so long as and at all times during which Intrexon holds any shares.

 

6.3             
Use of Proceeds. The Company shall apply the proceeds from the sale of the shares hereunder to ongoing
operations, or for such other uses as determined by the Company’s board of directors.

 

6.4             
Best Efforts. Each party will use its reasonable best efforts to satisfy in a timely fashion each of the
conditions to be satisfied by it under Section 8 of this Agreement.

 

6.5             
Press Release. The Company shall issue a press release announcing the transaction contemplated by this
Agreement and the Channel Agreement prior to the opening of the financial markets in New York City within four days immediately
following the date hereof. The Company shall provide Intrexon with a reasonable opportunity to review and comment on the press
release.

 

6.6             
Approval. In each case where the Company determines that the approval of Company investors or any exchange
or other listing upon which the Common Stock may be listed is required for the issuance of Common Stock to Intrexon, the Company
shall use commercially reasonable efforts to secure such approval as promptly as possible. In the event, notwithstanding the foregoing
obligation, the Company is unable to secure the approval with respect to the issuance of any shares to be issued hereunder, the
Company shall negotiate the terms of an alternate form of consideration of equivalent value to such unissued shares.

 

6.7             
Board Observer Rights.

 

(a)              
Upon the Technology Access Fee Closing, Intrexon will be entitled to maintain one person who is an employee,
officer, or director of Intrexon who is appointed by Company as an observer to the board of directors of the Company (the “Observer”).
If Intrexon does not already have an Observer on the board of directors of Company at or prior to the Technology Access Fee Closing,
the Company shall cause the President of Intrexon’s Human Therapeutics Division to be appointed as Observer. Intrexon may,
upon written notice to Company, change the identity of the Observer, and the right of Intrexon to maintain one Observer on the
board of directors of the Company shall continue until the Channel Agreement is terminated. The Observer shall be entitled to attend
all meetings of the Company’s board of directors and committees thereof as an observer (with no power to vote on any matter
before the board of directors) and shall be entitled to receive copies of all materials and receive all briefings provided to members
of the Company’s board of directors; provided that the Observer enters into a confidentiality agreement with the Company
in a form reasonably satisfactory to the Company; and provided, further, that the Company reserves the right to (i) exclude the
Observer from access to any board of directors’ materials or meetings or portion thereof if the Company believes that such
exclusion is reasonably necessary to preserve the attorney-client privilege, to protect highly confidential information or for
other similar reasons, or if the Company believes in good faith that the Observer has a conflict of interest, (ii) at the discretion
of the applicable committee, exclude the Observer from access to any meeting materials or meetings (or portion thereof) of the
nominating committee of the Company’s board of directors, compensation committee of the Company’s board of directors,
audit committee of the Company’s board of directors and any other committee of the Company’s board of directors performing
similar functions or which the listing rules of the NYSE Amex require to have such discretion.

 

    	15.

    	EXECUTION COPY
CONFIDENTIAL

    
 

(b)              
Subject to Section 10.14, Intrexon’s rights and the Company’s obligations under this Section 6.6
shall continue so long as the Channel Agreement is in force and terminate upon the termination of the Channel Agreement.

 

6.8             
No Poison Pill. The Company will not adopt any stockholder rights plan, “poison pill” or similar
arrangement, or adopt any anti-takeover provisions under its Charter documents, that would trigger any right, obligation or event
as a result of the issuance of the shares hereunder to Intrexon.

 

6.9             
No Standstill. The parties agree that Intrexon's acquisition of Common Stock pursuant to this Agreement
shall not trigger any standstill provisions set forth in any prior agreements between the parties including in the Stock Purchase
Agreement executed November 18, 2011 by and between Intrexon and Adeona Pharmaceuticals, Inc., and that any such standstill provisions
from prior agreements shall remain otherwise unaffected by this Agreement or the Channel Agreement.

 

6.10         
Intrexon Proposals. Notwithstanding any of the foregoing provisions of Section 6.9, the Company further
agrees that nothing herein shall limit the ability of the Observer or Intrexon to confidentially propose to the executive management
of the Company and its board of directors, and/or advocate for, any transaction between the Company and any third party unaffiliated
with Intrexon or its Affiliates.

 

6.11         
NYSE Amex Approval. In each case where the Company determines that the approval of the NYSE Amex (or any
other exchange upon which the Common Stock may be listed) is required for the issuance of Common Stock to Intrexon, the Company
shall use commercially reasonable efforts to secure such approval as promptly as possible. In the event, notwithstanding the foregoing
obligation, the Company is unable to secure the NYSE Amex (or any other exchange upon which the Common Stock may be listed) approval
with respect to the issuance of any shares to be issued hereunder, the Company shall negotiate the terms of an alternate form of
consideration of equivalent value to such unissued shares.

 

    	16.

    	EXECUTION COPY
CONFIDENTIAL

    
 

sECTION
7.    Conditions
to Closing.

 

7.1             
The obligation hereunder of the Company to issue and sell shares to Intrexon at each Closing is subject to the
satisfaction or waiver, at or before the Closing of the conditions set forth below. These conditions are for the Company’s
sole benefit and may be waived by the Company at any time in its sole discretion.

 

(a)              
Accuracy of Intrexon’s Representations and Warranties. The representations and warranties of Intrexon
shall be true and correct as of the date when made and as of the Closing Date as though made at that time, except for representations
and warranties that are expressly made as of a particular date, which shall be true and correct as of such date.

 

(b)              
No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have
been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits
the consummation of any of the transactions contemplated by this Agreement.

 

(c)               
Performance by Intrexon. Intrexon shall have performed, satisfied and complied in all material respects
with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied by Intrexon at
or prior to the Closing Date.

 

(d)              
Channel Partnership Agreement. The Channel Agreement shall have been entered into by the Company and Intrexon
and shall be in full force and effect.

 

(e)               
No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any governmental
authority shall have been commenced, and no investigation by any governmental authority shall have been threatened in writing against
Intrexon or any of the officers, directors or Affiliates of Intrexon seeking to restrain, prevent or change the transactions contemplated
by this Agreement, or seeking damages in connection with such transactions.

 

(f)               
Officer’s Certificate. On each Closing, Intrexon shall have delivered to the Company a certificate
signed by its Chief Financial Officer or Secretary on behalf of Intrexon, dated as of such Closing, confirming on behalf of Intrexon
the conditions precedent set forth in paragraphs (a), (b), (c) and (e) of this Section 7.1 as of such Closing; provided, however,
if the Company has elected to make the Milestone Cash Payment, the officer’s certificate to be delivered at the Milestone
Closing by Intrexon will address only the conditions precedent set forth in paragraphs (b) and (e) of this Section 7.1.

 

7.2             
The obligation hereunder of Intrexon to receive shares and consummate the transactions contemplated by this Agreement,
other than the payment by the Company of cash in lieu of issuance of any of the Milestone Shares or in lieu of the Field Expansion
Shares, is subject to the satisfaction or waiver, at or before each Closing, of each of the conditions set forth below. These conditions
are for Intrexon’s sole benefit and may be waived by Intrexon at any time in its sole discretion. For clarity, neither the
satisfaction nor the waiver of any of the events, circumstances, deliveries or conditions set forth below is a condition precedent
to the obligation of Intrexon to accept the any cash payments in lieu of the Company’s issuing the Milestone Shares or the
Field Expansion Shares to Intrexon.

 

    	17.

    	EXECUTION COPY
CONFIDENTIAL

    
 

(a)              
Accuracy of the Company’s Representations and Warranties. Each of the representations and warranties
of the Company in this Agreement shall be true and correct as of the Closing Date, except for representations and warranties that
speak as of a particular date, which shall be true and correct as of such date. 

 

(b)              
Performance by the Company. The Company shall have performed, satisfied and complied in all material respects
with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company
at or prior to the Closing Date.

 

(c)               
Channel Partnership Agreement. The Channel Agreement shall have been entered into by the Company and Intrexon
and shall be in full force and effect.

 

(d)              
No Suspension, Etc. Trading in the common stock shall not have been suspended by the Commission or the
NYSE Amex.

 

(e)               
No Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have
been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits
the consummation of any of the transactions contemplated by this Agreement.

 

(f)               
No Proceedings or Litigation. No action, suit or proceeding before any arbitrator or any governmental
authority shall have been commenced, and no investigation by any governmental authority shall have been threatened in writing against
the Company or any of the officers, directors or Affiliates of the Company seeking to restrain, prevent or change the transactions
contemplated by this Agreement, or seeking damages in connection with such transactions.

 

(g)              
Execution of Rights Agreement. On the date of the Technology Access Fee Closing, each party shall have
delivered its signature to the First Amendment to Registration Rights Agreement substantially in the form attached as Exhibit
A to this Agreement to the other party, and such agreement shall be in full force and effect as of the Closing Date.

 

(h)              
Opinion. Counsel for the Company shall have delivered to Intrexon opinion letters containing legal opinions
substantially in the form attached hereto as Exhibit B.

 

(i)                
Officer’s Certificate. On each Closing, the Company shall have delivered to Intrexon a certificate
signed by its Chief Financial Officer or Secretary on behalf of the Company (the “Officer’s Certificate”),
dated as of such Closing, confirming on behalf of the Company the conditions precedent set forth in paragraphs (a), (b), (d), (e),
(i) and (j) of this Section 7.2 as of such Closing, and attaching and certifying a copy of the resolutions of the Company’s
board of directors referred to in the last sentence of Section 3.2.

 

(j)                
No Material Adverse Effect. Since the date of this Agreement, there shall not have occurred any Material
Adverse Effect.

 

    	18.

    	EXECUTION COPY
CONFIDENTIAL

    
 

(k)              
Board Observer. The President of Intrexon’s Protein Production Division, or someone else identified
in advance by Intrexon, shall have been appointed as, or have been previously appointed as, Observer.

 

(l)                
Approvals. Any requisite shareholder, board, or exchange approvals relating to the issuance of the Milestone
Shares or the Field Expansion Shares (as the case may be) have been obtained in advance by Company.

 

 

sECTION
8.    Notices.

 

All notices or other communications which
are required or permitted hereunder shall be in writing and addressed as follows:

 

	If to the Company:	Synthetic Biologics, Inc.
	 	617 Detroit Street, Suite 100
	 	Ann Arbor, MI  48104
	 	Attention:  Chief Executive Officer
	 	Fax No.: (734) 332-7878
	 	 
	If to Intrexon:	Intrexon Corporation
	 	20358 Seneca Meadows Parkway
	 	Germantown, MD 20876
	 	Attention: Legal Department
	 	Fax No.:  (301) 556-9902

  

or to such other address as the party to
whom notice is to be given may have furnished to the other party in writing in accordance herewith. Any such communication shall
be deemed to have been given when delivered if personally delivered or sent by facsimile (provided that the party providing such
notice promptly confirms receipt of such transmission with the other party by telephone), on the business day after dispatch if
sent by a nationally-recognized overnight courier and on the third business day following the date of mailing if sent by certified
mail, postage prepaid, return receipt requested.

 

 

sECTION
9.    Miscellaneous.

 

9.1             
Fees and Expenses. Each party shall pay the fees and expenses of its advisors, counsel, accountants and
other experts, if any, and all other expenses, incurred by such party incident to the negotiation, preparation, execution, delivery
and performance of this Agreement.

 

9.2             
Waivers and Amendments. Neither this Agreement nor any provision hereof may be changed, waived, discharged,
terminated, modified or amended except upon the written consent of the parties hereto.

 

    	19.

    	EXECUTION COPY
CONFIDENTIAL

    
 

9.3             
Headings. The headings of the various sections of this Agreement have been inserted for convenience of
reference only and shall not be deemed to be part of this Agreement.

 

9.4             
Severability. If any provision hereof should be held invalid, illegal or unenforceable in any respect,
then, to the fullest extent permitted by law, (a) all other provisions hereof shall remain in full force and effect and shall be
liberally construed in order to carry out the intentions of the Parties as nearly as may be possible and (b) the parties shall
use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s)
which, insofar as practical, implement the purposes of such provision(s) in this Agreement.

 

9.5             
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State
of New York as applied to contracts entered into and performed entirely in the State of New York by New York residents, without
regard to conflicts of law principles.

 

9.6             
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall constitute
an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or
more counterparts have been signed by each party hereto and delivered to the other parties.

 

9.7             
Successors and Assigns. Except as otherwise expressly provided herein, the provisions hereof shall inure
to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto, provided
that Intrexon shall not assign its rights or obligations hereunder unless Intrexon assigns such rights in whole and not in part
to an assignee of such rights and obligations which shall agree in writing with the Company to be bound by this Agreement and that
Intrexon’s rights under Sections 6.3, 6.4, 6.5 and 7 shall not be assignable.

 

9.8             
No Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their
respective permitted successors and assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other
person.

 

9.9             
Expenses. Each party shall pay all costs and expenses that it incurs with respect to the negotiation,
execution, delivery and performance of this Agreement.

 

9.10         
Entire Agreement. This Agreement (including the Schedule of Exceptions), the Channel Agreement, the Rights
Agreement and other documents delivered pursuant hereto and thereto, including the exhibits, constitute the full and entire understanding
and agreement between the parties with regard to the subjects hereof and thereof. Except as explicitly set forth herein, nothing
in this Agreement is intended to alter the rights or obligations of the parties pursuant to the Stock Purchase Agreement executed
November 18, 2011 by and between Intrexon and Adeona Pharmaceuticals, Inc.

 

9.11         
Publicity. Except as otherwise provided herein or in the Channel Agreement, no party shall issue any press
releases or otherwise make any public statement with respect to the transactions contemplated by this Agreement without the prior
written consent of the other party, except as may be required by applicable law or regulations, in which case such party shall
provide the other parties with reasonable notice of such publicity and/or opportunity to review such disclosure.

 

    	20.

    	EXECUTION COPY
CONFIDENTIAL

    
 

9.12         
Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection
with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement
shall be construed against the drafting Party shall not apply.

 

9.13         
Further Assurances. From and after the date of this Agreement, upon the reasonable request of Intrexon
or the Company, the Company and Intrexon shall execute and deliver such instruments, documents and other writings as may be reasonably
necessary or desirable to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.

 

9.14         
Company Sale. For purposes of this Agreement, a “Company Sale” shall mean the sale
of the Company, whether in a single transaction or in a series of related transactions that are consummated contemporaneously
(or consummated pursuant to contemporaneous agreements), to one or more unaffiliated third parties on an arm’s-length
basis, pursuant to which such unaffiliated third party or parties acquires (i) (whether by merger, consolidation, sale
or transfer of capital stock, recapitalization, or otherwise) more than fifty percent (50%) of the Company's common stock or
(ii) all or substantially all of the assets of the Company determined on a consolidated basis.

 

 

 

[Remainder of page intentionally left blank.]

 

    	21.

    	EXECUTION COPY
CONFIDENTIAL

    
 

In
Witness Whereof, the parties hereto have caused this Stock Issuance Agreement to be executed by their duly authorized
representatives as of the day and year first above written.

 

	 	
        SYNTHETIC BIOLOGICS, INC.

         

        By: /s/ Jeffrey Riley

        Name:Jeffrey Riley

        Title:Chief Executive Officer, President,
        and Director

         

         

	 	 
	 	 
	 	
         

         

        INTREXON CORPORATION

        

        

         

        By: /s/Saiid Zarrabian

        Name: Saiid Zarrabian

        Title: President of Protein
        Production Division,

        and Senior Vice President

         

         

	 	 
	 	 

SIGNATURE PAGE FOR STOCK ISSUANCE AGREEMENT

 

    	22.

    	 

    
 

 

 

Exhibit A

 

FORM OF FIRST AMENDMENT
TO REGISTRATION RIGHTS AGREEMENT

 

 

    	23

    	 

    
 

Exhibit B

 

FORM OF LEGAL OPINION

 

		1.	The Company has been duly incorporated and is a validly existing corporation in good standing under
the laws of the State of Nevada.

 

		2.	The Company has the requisite corporate power to own, lease and operate its property and assets,
and to conduct its business as described in the SEC Documents.

 

		3.	The Company is duly qualified to do business as a foreign corporation and is in good standing in
the State of Michigan.

 

		4.	The Company has the requisite corporate power to execute, deliver and perform its obligations under
the Agreement, the Channel Agreement and the Rights Agreement (collectively, the “Transaction Documents”), including,
without limitation, to issue, sell and deliver the shares as contemplated by the Agreement.

 

		5.	All corporate action on the part of the Company necessary for the authorization, execution and
delivery of the Transaction Documents by the Company, the authorization, sale, issuance and delivery of the shares and the performance
by the Company of its obligations to be performed at the Closing under the Transaction Documents has been taken. Each of the Transaction
Documents has been duly and validly authorized, executed and delivered by the Company. The Agreement and the Rights Agreement (together,
the “Equity Documents”) each constitutes a valid and binding agreement of the Company enforceable against the
Company in accordance with its respective terms.

 

		6.	The Company has the authorized capital stock as set forth in the SEC Documents. The shares have
been duly authorized and, when issued, sold and delivered against payment therefor in accordance with the terms of the Agreement,
will be validly issued, fully paid and nonassessable.

 

		7.	There are no pre-emptive rights or similar rights contained in the Company’s Articles of
Incorporation, as amended, or Bylaws, as amended, or any Material Agreement.

 

		8.	The execution and delivery of the Equity Documents and the issuance of the shares pursuant thereto
do not violate any provision of the Company’s Articles of Incorporation or Bylaws, do not constitute a default under or a
material breach of any Material Agreement and do not (a) violate any U. S. Federal or state statute, rule or regulation which in
the experience of such counsel is typically applicable to transactions of the nature contemplated by the Equity Documents or (b)
violate any order, writ, judgment, injunction, decree, determination or award which has been entered against the Company and of
which such counsel is aware, except, with respect to clauses (a) and (b), where such violation would not materially and adversely
affect the Company.

 

 

    	-i-

    	 

    
 

 

		9.	To the knowledge of such counsel, there is no action, proceeding or investigation pending or overtly
threatened against the Company before any court or administrative agency that questions the validity of the Transaction Documents
or that could reasonably be expected to result, either individually or in the aggregate, in a material adverse effect on the Company.

 

		10.	All consents, approvals, authorizations, or orders of, and filings, registrations and qualifications
with any U.S. Federal or state regulatory authority or governmental body required for the issuance of the shares have been made
or obtained, except (a) for the filing of a Form D pursuant to Securities and Exchange Commission Regulation D and (b) and any
requisite blue sky filing(s).

 

		11.	Subject to the accuracy of Intrexon’s representations in Section 4 of the Agreement and assuming
(a) that neither the Company nor any person acting on behalf of the Company has offered or sold the shares by any form of general
solicitation or general advertising within the meaning of Rule 502(c) of Regulation D promulgated (the “Regulation D”)
under the Securities Act; (b) that no offerings or sales of securities of the Company after the date hereof in a transaction can
be “integrated” with any sales of the shares, the offer and sale of the shares in conformity with the terms of the
Agreement constitute transactions that are exempt from the registration requirements of the Securities Act of 1933, as amended,
subject to the timely filing of a Form D pursuant to Regulation D.

 

		12.	The Company is not, and, after giving effect to the offering and sale of the shares and the application
of the proceeds thereof in accordance with the business plans of the Company to which such counsel is aware, will not be an “investment
company” as defined in the Investment Company Act of 1940, as amended.

 

		13.	To the knowledge of such counsel, there are no written contracts, agreements or understandings
between the Company and any person granting such person the right (other than rights which have been waived in writing or otherwise
satisfied) to require the Company to include any securities of the Company in any registration statement contemplated by Section
2(a) of the Rights Agreement.

  

    	-ii-EXECUTION
COPY

CONFIDENTIAL

  

 

FIRST AMENDMENT TO REGISTRATION RIGHTS
AGREEMENT

 

This First Amendment
to Registration Rights Agreement (this “Amendment”) is made and entered into as of August 6, 2012, by and among
Synthetic Biologics, Inc., a Nevada corporation, previously known as Adeona Pharmaceuticals, Inc. (the “Company”),
and Intrexon Corporation, a Virginia corporation (“Intrexon”) to amend the Registration Rights Agreement dated
December 5, 2011, by and among the Company and Intrexon (the “Registration Rights Agreement”).

 

WHEREAS, the Company
and Intrexon entered into the Registration Rights Agreement and that certain Stock Purchase Agreement between the Company and Intrexon
dated as of November 18, 2011 (the “Purchase Agreement”) in connection with their execution and delivery of
that certain Exclusive Channel Collaboration Agreement dated November 18, 2011, 2011, for the development and commercialization
of products for the treatment of pulmonary arterial hypertension (the “Original ECC”);

 

WHEREAS, concurrently
with the execution and delivery of this Amendment, the Company and Intrexon will execute and deliver a Stock Issuance Agreement
between the Company and Intrexon (the “Issuance Agreement”) in connection with their execution and delivery
of an exclusive channel collaboration with respect to the development and commercialization of products based on exogenous recombinant
human antibodies for the treatment of certain toxins and infectious diseases (the “Second ECC”);

 

WHEREAS, pursuant to
the terms of the Issuance Agreement and the Second ECC, the Company will issue and sell to Intrexon, upon Intrexon’s request
to the Company, certain shares of the Company’s common stock in exchange for rights to certain technology of Intrexon;

 

NOW THEREFORE, the Company
and Intrexon hereby agree to amend the Registration Rights Agreement as follows:

 

1.                 
The following defined terms shall be added to Section 1:

 

(a)               
“Approval Milestone Shares” shall have the meaning set forth in the Issuance Agreement.

 

(b)              
“Field Expansion Fee Shares” shall have the meaning set forth in the Issuance Agreement.

 

(c)               
“IND Milestone Shares” shall have the meaning set forth in the Issuance Agreement.

 

(d)              
“Issuance Agreement” shall mean that certain Stock Issuance Agreement, dated August 6, 2012, by and between
the Company and Intrexon.

 

(e)               
“Technology Access Fee Shares” shall have the meaning set forth in the Issuance Agreement.

 

    	1

    	EXECUTION COPY
CONFIDENTIAL

    
 

2.                 
The definition of “Filing Date” shall be amended and replaced in its entirety with the following:

 

(a)               
“Filing Date” means, with respect to the First Tranche Shares, April 4, 2012, and, with respect to the
Second Tranche Shares, the Technology Access Fee Shares, the IND Milestone Shares, the Approval Milestone Shares, and the Field
Expansion Shares, April 30, 2013..

 

3.                 
The definition of “Registrable Securities” shall be amended and replaced in its entirety with the following:

 

(a)               
“Registrable Securities” means the First Tranche Shares and Second Tranche Shares (as such terms are
defined in the Purchase Agreement) as well as the Technology Access Fee Shares, the IND Milestone Shares, the Approval Milestone
Shares, and the Field Expansion Shares (as such terms are defined in the Issuance Agreement) issued or issuable to Intrexon and
any securities issued with respect to, or in exchange for or in replacement of such shares of Common Stock upon any stock split,
stock dividend, recapitalization, subdivision, merger or similar event; provided, however, that the applicable Holder has completed
and delivered to the Company a Selling Stockholder Questionnaire; and provided further that such securities shall no longer be
deemed Registrable Securities if such securities have been sold pursuant to a Registration Statement, or (ii) such shares have
been sold in compliance with Rule 144 or all such shares may be sold without limitation pursuant to Rule 144.

 

4.                 
Subsection (b) of Section 7 shall be amended and replaced in its entirety with the following:

 

(a)               
Entire Agreement; Amendment. This Agreement, the Purchase Agreement and the Issuance Agreement contain the entire
understanding and agreement of the parties with respect to the matters covered hereby and, except as specifically set forth herein,
in the Purchase Agreement, or in the Issuance Agreement, neither the Company nor any Holder make any representation, warranty,
covenant or undertaking with respect to such matters, and they supersede all prior understandings and agreements with respect to
said subject matter, all of which are merged herein. No provision of this Agreement may be waived or amended other than by a written
instrument signed by the Company and the Holders of at least a majority of all Registrable Securities then outstanding. Any amendment
or waiver effected in accordance with this Section 7(b) shall be binding upon each Holder (and their permitted assigns) and
the Company.

 

5.                 
All other provisions of the Registration Rights Agreement shall remain in effect.

 

 

 

 

 

[Remainder of page intentionally
left blank.]

 

    	2

    	EXECUTION COPY
CONFIDENTIAL

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Amendment to Registration Rights Agreement to be duly executed by their respective authorized
officers as of the date first above written.

 

 

 

	 	
        SYNTHETIC BIOLOGICS, INC.

         

        By:/s/ Jeffrey Riley

        Name: Jeffrey Riley

        Title: Chief Executive Office, President,
        and Director

         

         

	 	 
	 	
        INTREXON CORPORATION

         

        By:/s/Saaid Zarrabian

        Name: Saiid Zarrabian

        Title: President of Protein Production
        Division, and

        Senior Vice President

         

         

 

 

 

 

SIGNATURE PAGE TO FIRST AMENDMENT TO REGISTRATION

RIGHTS AGREEMENT

 

    	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]